Anyone watching this one?

Ran up past $3 over the summer

InspireMD (NYSEMKT:NSPR): Q3 EPS of -$0.36 beats by $0.14.

Revenue of $0.63M (+133.3% Y/Y) misses by $0.27M.

Press Release

Quarter Ended September 30, 2015 Financial Results

Revenue for the third quarter ended September 30, 2015 increased $0.3 million to $0.6 million compared to $0.3 million during the same period in 2014. The increase was predominately driven by sales of $0.3 million of our new product CGuard" EPS, our carotid product, which was launched in October 2014. Sales of CGuard" EPS during the three months ended September 30, 2015 were predominately driven by initial sales to our new strategic distribution partner, Penumbra, Inc.

The company's gross profit for the quarter ended September 30, 2015 was $0.1 million compared to a gross loss of $0.1 million for the same period in 2014. The improvement of 217.1% was largely attributable to the increase in product revenues and a decrease of write-offs of inventory of MGuard" Prime EPS. These improvements in gross profit, however, were partially offset by an increase in labor and material costs attributable to higher revenues.

Total operating expenses for the quarter ended September 30, 2015 were $3.5 million, a decrease of 45.3% compared to $6.4 million for the same period in 2014. This decrease was primarily due to a reduction of expenses related to MGuard" Prime EPS's MASTER II trial, which was suspended in October 2014, a decrease in compensation related expenses and other savings associated with our cost reduction plan.

Recent Operating Highlights:

COMMERCIAL

• Announced full European market launch of CGuard" in late September at CIRSE 2015 by Penumbra Inc., a global market leader in the interventional neuroradiology and peripheral vascular markets.
  
  
• Reported sequential revenue increase of 85% for CGuard".
  
  
• On track for full Penumbra commercial launch of CGuard" in Q4 of 2015.